Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401642 · ClinicalTrials.gov registry record · Phase 4
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
A Phase 4 study of Migraine, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06401642 is a Phase 4 study of Migraine that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 200 participants, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06401642, a Phase 4 study of Migraine, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.
Conditions Studied
Interventions
- DRUG Zavegepant
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-03-22 |
| Est. Completion | 2027-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06401642
The ClinicalTrials.gov registry entry for NCT06401642 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (44% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Zavegepant is the first listed.
NCT06401642 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06401642 about?
NCT06401642 is a clinical study titled "Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications". Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related pe...
What is the current status of trial NCT06401642?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2024-03-22. Estimated completion is 2027-03.
What conditions does trial NCT06401642 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06401642?
The interventions under investigation include: Zavegepant (DRUG).
Who is sponsoring clinical trial NCT06401642?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401642 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.